Investor Relations

Corporate Profile

Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest SEC Filings

Form Filing date Description



Simplified registration form


Report of unscheduled material events or corporate event

Scroll to Top